DRL's USA facility gets 2 observations from USFDA

The USFDA completed aforementioned inspection and issued form-483 with two observations.

Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company reported a consolidated net profit of Rs 1,594 crore for the quarter ended March 2025 (Q4FY25), marking a 22% year-on-year increase from Rs 1,307 crore in the same period last year. Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 crore in Q4FY24.

The counter shed 0.35% to end at Rs 1,230.50 on Friday, 16 May 2025.

Powered by Capital Market - Live News